Miethke Marcus, Marahiel Mohamed A
Philipps Universität Marburg, FB Chemie Biochemie, Hans Meerwein Strasse, D-35032 Marburg, Germany.
Microbiol Mol Biol Rev. 2007 Sep;71(3):413-51. doi: 10.1128/MMBR.00012-07.
High-affinity iron acquisition is mediated by siderophore-dependent pathways in the majority of pathogenic and nonpathogenic bacteria and fungi. Considerable progress has been made in characterizing and understanding mechanisms of siderophore synthesis, secretion, iron scavenging, and siderophore-delivered iron uptake and its release. The regulation of siderophore pathways reveals multilayer networks at the transcriptional and posttranscriptional levels. Due to the key role of many siderophores during virulence, coevolution led to sophisticated strategies of siderophore neutralization by mammals and (re)utilization by bacterial pathogens. Surprisingly, hosts also developed essential siderophore-based iron delivery and cell conversion pathways, which are of interest for diagnostic and therapeutic studies. In the last decades, natural and synthetic compounds have gained attention as potential therapeutics for iron-dependent treatment of infections and further diseases. Promising results for pathogen inhibition were obtained with various siderophore-antibiotic conjugates acting as "Trojan horse" toxins and siderophore pathway inhibitors. In this article, general aspects of siderophore-mediated iron acquisition, recent findings regarding iron-related pathogen-host interactions, and current strategies for iron-dependent pathogen control will be reviewed. Further concepts including the inhibition of novel siderophore pathway targets are discussed.
在大多数致病和非致病细菌及真菌中,高亲和力铁摄取是由铁载体依赖性途径介导的。在铁载体合成、分泌、铁清除以及铁载体传递的铁摄取及其释放机制的表征和理解方面已经取得了相当大的进展。铁载体途径的调控在转录和转录后水平揭示了多层网络。由于许多铁载体在毒力过程中发挥关键作用,共同进化导致了哺乳动物对铁载体进行中和以及细菌病原体对其进行(再)利用的复杂策略。令人惊讶的是,宿主还开发了基于铁载体的基本铁传递和细胞转化途径,这对诊断和治疗研究具有重要意义。在过去几十年中,天然和合成化合物作为铁依赖性感染及其他疾病治疗的潜在药物受到了关注。使用各种作为“特洛伊木马”毒素的铁载体 - 抗生素缀合物和铁载体途径抑制剂,在抑制病原体方面取得了有前景的结果。在本文中,将综述铁载体介导的铁摄取的一般方面、关于铁相关病原体 - 宿主相互作用的最新发现以及铁依赖性病原体控制的当前策略。还将讨论包括抑制新型铁载体途径靶点在内的其他概念。